Clinical Trials Logo

Evans Syndrome clinical trials

View clinical trials related to Evans Syndrome.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05937828 Recruiting - Clinical trials for Immune Thrombocytopenia

OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia

OBS'CEREVANCE
Start date: September 1, 2010
Phase:
Study type: Observational [Patient Registry]

From 2004, OBS'CEREVANCE is a national real-world prospective clinical cohort of patients with auto-immune cytopenia of pediatric-onset : Immune thrombocytopenia (ITP), Autoimmune Hemolytic anemia (AIHA), or Evans syndrome (all bi or tri cytopenias). Thanks to the collaboration of the 30 French pediatric hematologic centers, this cohort supports all of the Rare Disease Centre CEREVANCE (Centre de Référence National des Cytopénies Auto-Immunes de l'Enfant) missions for care, education and research. Specifically, this original unbiased database allows to describe the long-term health of adult patients, to identify the heterogenous genetic underlying pathophysiologic contexts, and to study the benefit-risk balance of treatments, including the growing development of targeted therapies.

NCT ID: NCT03918265 Recruiting - Clinical trials for Autoimmune Hemolytic Anemia

Tacrolimus Treatment for Refractory Autoimmune Cytopenia

Start date: May 4, 2019
Phase: Phase 4
Study type: Interventional

Autoimmune cytopenia, including autoimmune hemolytic anemia (AIHA), pure red cell aplasia (PRCA), Evans syndrome (ES), usually has good responses to steroids therapies as first line, but there is a considerable percentage of patients who relapse, become refractory or dependent on steroids to maintain an acceptable level of hemoglobin or platelets. The effects of the second line therapy are also not satisfactory and sometimes not available. The investigators aim to explore the efficacy and side-effect of tacrolimus for refractory autoimmune cytopenia.